Loading…
Reported covered position: Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the President
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · 3A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · 2A
Source: Senate LDA
| CENTER FOR RESPONSIBLE LENDING |
| 8 |
| 2025–2026 |
| COUNCIL ON FOUNDATIONS INC. | 8 | 2025–2026 |
| LOWE'S COMPANIES INC | 8 | 2025–2026 |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 8 | 2025–2026 |
| REPUBLIC SERVICES, INC. | 8 | 2025–2026 |
| TELNYX | 8 | 2025–2026 |
| VAPOR TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| WALGREEN COMPANY | 8 | 2025–2026 |
| ALKERMES, INC. | 7 | 2025–2026 |
| EASTMAN CHEMICAL COMPANY | 7 | 2025–2026 |
| GLAS INC. | 7 | 2025–2026 |
| PET FOOD INSTITUTE | 7 | 2025–2026 |
| RTX CORPORATION AND AFFILIATES | 7 | 2025–2026 |
| VIASAT, INC. | 7 | 2025–2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 6 | 2025 |
| PNC FINANCIAL INC. | 6 | 2025–2026 |
| WALMART INC | 6 | 2025–2026 |
| COHESITY, INC. | 5 | 2025–2026 |
| WAYMO LLC | 5 | 2025–2026 |
| EXPEDIA GROUP | 4 | 2025 |
| Fresenius Kabi | 3 | 2025 |
| INTERFOR CORPORATION | 3 | 2026 |
| CIGAR ASSOCIATION OF AMERICA | 2 | 2025 |
| SKYDIO, INC. | 1 | 2026 |
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · 1A
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERFOR CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to lumber tariffs
Issues related to housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to spectrum policy and satellite communications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · third_quarter · Q3
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · third_quarter · Q3
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · third_quarter · Q3
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2026 · third_quarter · Q3
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · third_quarter · Q3
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EASTMAN CHEMICAL COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Advice and assistance on chemical industry and recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PET FOOD INSTITUTE via S-3 GROUP
2026 · third_quarter · Q3
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2026 · third_quarter · Q3
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · fourth_quarter · RR
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
INTERFOR CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to lumber tariffs
Issues related to housing policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERFOR CORPORATION via S-3 GROUP
2026 · second_quarter · RR
Issues related to lumber tariffs and US housing policy
Issues related to lumber tariffs and US housing policy
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to spectrum policy and satellite communications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · second_quarter · Q2
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · second_quarter · Q2
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · second_quarter · Q2
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2026 · second_quarter · Q2
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · second_quarter · Q2
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EASTMAN CHEMICAL COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Advice and assistance on chemical industry and recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PET FOOD INSTITUTE via S-3 GROUP
2026 · second_quarter · Q2
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2026 · second_quarter · Q2
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to spectrum policy
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · first_quarter · Q1
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY CORPORATION via S-3 GROUP
2026 · first_quarter · Q1
Issues related to fuel cell tax credits
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2026 · first_quarter · Q1
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · first_quarter · Q1
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · first_quarter · Q1
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2026 · first_quarter · Q1
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2026 · first_quarter · Q1
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · first_quarter · Q1
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · first_quarter · Q1
Issues related to pharmacy, pharmacist provider status, and Medicare reimbursement
Issues related to the provider status of pharmacists under Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · Q1
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION OF MANUFACTURERS OF SMOKING ALTERNATIVES via S-3 GROUP
2026 · first_quarter · Q1
Support for consistent and transparent regulation of non-combustible tobacco and/or nicotine products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EASTMAN CHEMICAL COMPANY via S-3 GROUP
2026 · first_quarter · Q1
Advice and assistance on chemical industry and recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PET FOOD INSTITUTE via S-3 GROUP
2026 · first_quarter · Q1
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Provide more efficient oversight of pet food and pet food products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2026 · first_quarter · Q1
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · 4T
Issues related to the distribution of health care products, trade policy, and tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to spectrum policy
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2025 · fourth_quarter · Q4
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to autonomous vehicles
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Product applications related to the FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PNC FINANCIAL INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2025 · fourth_quarter · 4A
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COUNCIL ON FOUNDATIONS INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Strategies and policy advice on tax policy matters with respect to the philanthropic sector
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PATTERN ENERGY GROUP SERVICES LP via S-3 GROUP
2025 · fourth_quarter · Q4
Issues regarding renewable energy and electronic transmission projects
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
REPUBLIC SERVICES, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR RESPONSIBLE LENDING via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to financial products and lending
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2025 · fourth_quarter · Q4
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to pharmacy, pharmacist provider status, and Medicare reimbursement
Issues related to the provider status of pharmacists under Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RTX CORPORATION AND AFFILIATES via S-3 GROUP
2025 · fourth_quarter · Q4
FY26 Defense Appropriations and Authorizations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2025 · fourth_quarter · Q4
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2025 · fourth_quarter · Q4
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE